



Kronans Apotek to record an impairment with an impact of approximately EUR 16 million to Oriola's net result

Oriola Corporation Stock Exchange Release 19 December 2025 at 1:00 p.m. EET

Kronans Apotek to record an impairment with an impact of approximately EUR 16 million to Oriola's net result

The integration in Oriola's joint venture company Kronans Apotek and the transition to one ERP system have been completed during this year, however both have required more time than expected. Due to this, Kronans Apotek will record a goodwill impairment of approximately SEK 349 million in its fourth quarter results.

Oriola's share of the impairment is approximately SEK 175 million or approximately EUR 16 million and will be recorded in the share of results in joint venture in the fourth quarter.

The value of Oriola's investment in Kronans Apotek after the impairment totals approximately EUR 187 million. The impairment will not affect the distributable funds of the parent company, Oriola Corporation.

The impairment will be recorded in Oriola's fourth quarter 2025 results and will have no effect on the Group's cash flow or adjusted EBITDA. Oriola's outlook for 2025 remains unchanged. Oriola will publish its Financial Statements Release for 2025 on 25 February 2026.

Further information:

Mats Danielsson
CFO
tel. +358 50 394 8575
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:

Nasdaq Helsinki Ltd.
Key media